Vir Biotechnology(VIR)
$9.15-0.10 (-1.08%)
VIR
Vir Biotechnology financials statements
$9.15
At close:-0.10 (-1.08%)
Want to see VIR full AI Analyst Report?
Vir Biotechnology (VIR) Ratios
1,581 Followers
Vir Biotechnology Ratios
VIR's free cash flow for Q3 2026 was $-106.11M. For the 2026 fiscal year, VIR's free cash flow was decreased by $-34.00K and operating cash flow was $-106.08M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 |
| Quick Ratio | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 |
| Cash Ratio | 2.52 | 1.86 | 1.38 | 1.66 | 1.02 |
| Solvency Ratio | -1.79 | -2.04 | -1.81 | 0.72 | 1.02 |
| Operating Cash Flow Ratio | -4.22 | -3.73 | -4.44 | 3.25 | -0.14 |
| Short-Term Operating Cash Flow Coverage | -44.53 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 276.53M | $ 794.03M | $ 1.26B | $ 1.79B | $ 1.04B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.07 | 0.06 | 0.05 | 0.07 |
| Debt-to-Equity Ratio | 0.24 | 0.09 | 0.08 | 0.06 | 0.10 |
| Debt-to-Capital Ratio | 0.20 | 0.08 | 0.07 | 0.06 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.31 | 1.22 | 1.21 | 1.35 | 1.36 |
| Debt Service Coverage Ratio | -51.89 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.35 | 0.72 | 0.93 | 0.97 | 1.06 |
| Net Debt to EBITDA | 0.10 | 0.25 | 0.18 | -0.86 | -0.49 |
| Profitability Margins | |||||
| Gross Profit Margin | 82.92% | -545.03% | -564.69% | 61.57% | 53.09% |
| EBIT Margin | -682.68% | -705.44% | -767.10% | 51.56% | 38.41% |
| EBITDA Margin | -665.65% | -685.82% | -744.53% | 51.98% | 38.94% |
| Operating Profit Margin | -682.68% | -791.27% | -794.04% | 51.56% | 38.41% |
| Pretax Profit Margin | -638.56% | -704.95% | -728.93% | 46.68% | 50.19% |
| Net Profit Margin | -638.87% | -703.40% | -713.69% | 31.92% | 48.25% |
| Continuous Operations Profit Margin | -638.87% | -703.40% | -713.76% | 31.92% | 48.25% |
| Net Income Per EBT | 100.05% | 99.78% | 97.91% | 68.39% | 96.14% |
| EBT Per EBIT | 93.54% | 89.09% | 91.80% | 90.54% | 130.67% |
| Return on Assets (ROA) | -43.68% | -37.31% | -32.05% | 18.41% | 27.05% |
| Return on Equity (ROE) | -57.23% | -45.37% | -38.68% | 24.82% | 36.92% |
| Return on Capital Employed (ROCE) | -51.43% | -45.90% | -39.25% | 36.36% | 26.08% |
| Return on Invested Capital (ROIC) | -50.94% | -45.53% | -38.15% | 24.82% | 25.02% |
| Return on Tangible Assets | -44.78% | -37.99% | -32.72% | 18.74% | 27.76% |
| Earnings Yield | -52.44% | -52.19% | -45.58% | 15.37% | 9.72% |
| Efficiency Ratios | |||||
| Receivables Turnover | 19.04 | 0.00 | 0.00 | 0.00 | 1.42 |
| Payables Turnover | 1.19 | 94.20 | 90.44 | 96.69 | 78.80 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.58 | 0.60 | 0.52 | 8.59 | 8.42 |
| Asset Turnover | 0.07 | 0.05 | 0.04 | 0.58 | 0.56 |
| Working Capital Turnover Ratio | 0.10 | 0.06 | 0.05 | 1.00 | 1.16 |
| Cash Conversion Cycle | -286.50 | -3.87 | -4.04 | -3.77 | 252.96 |
| Days of Sales Outstanding | 19.17 | 0.00 | 0.00 | 0.00 | 257.60 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 305.66 | 3.87 | 4.04 | 3.77 | 4.63 |
| Operating Cycle | 19.17 | 0.00 | 0.00 | 0.00 | 257.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.83 | -3.28 | -5.81 | 12.54 | -0.37 |
| Free Cash Flow Per Share | -2.86 | -3.33 | -5.97 | 12.03 | -0.53 |
| Dividend Paid and CapEx Coverage Ratio | -81.08 | -61.14 | -36.10 | 24.46 | -2.18 |
| Capital Expenditure Coverage Ratio | -81.08 | -61.14 | -36.10 | 24.46 | -2.18 |
| Operating Cash Flow Coverage Ratio | -2.10 | -4.56 | -6.25 | 13.00 | -0.35 |
| Operating Cash Flow to Sales Ratio | -5.71 | -6.02 | -9.04 | 1.03 | -0.04 |
| Free Cash Flow Yield | -47.48% | -45.36% | -59.31% | 47.53% | -1.28% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.91 | -1.92 | -2.19 | 6.51 | 10.29 |
| Price-to-Sales (P/S) Ratio | 12.18 | 13.48 | 15.66 | 2.08 | 4.96 |
| Price-to-Book (P/B) Ratio | 1.09 | 0.87 | 0.85 | 1.62 | 3.80 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.11 | -2.20 | -1.69 | 2.10 | -78.35 |
| Price-to-Operating Cash Flow Ratio | -2.13 | -2.24 | -1.73 | 2.02 | -114.28 |
| Price-to-Earnings Growth (PEG) Ratio | 0.11 | 0.12 | 0.01 | -1.47 | -0.04 |
| Enterprise Value Multiple | -1.73 | -1.72 | -1.92 | 3.14 | 12.26 |
| Enterprise Value | 788.08M | 875.00M | 1.23B | 2.64B | 5.23B |
| EV to EBITDA | -1.73 | -1.72 | -1.92 | 3.14 | 12.26 |
| EV to Sales | 11.50 | 11.79 | 14.30 | 1.63 | 4.77 |
| EV to Free Cash Flow | -1.99 | -1.93 | -1.54 | 1.65 | -75.32 |
| EV to Operating Cash Flow | -2.01 | -1.96 | -1.58 | 1.58 | -109.86 |
| Tangible Book Value Per Share | 5.35 | 8.26 | 11.56 | 15.30 | 10.64 |
| Shareholders’ Equity Per Share | 5.52 | 8.44 | 11.86 | 15.67 | 11.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.00 | 0.02 | 0.32 | 0.04 |
| Revenue Per Share | 0.49 | 0.54 | 0.64 | 12.18 | 8.43 |
| Net Income Per Share | -3.16 | -3.83 | -4.59 | 3.89 | 4.07 |
| Tax Burden | 1.00 | 1.00 | 0.98 | 0.68 | 0.96 |
| Interest Burden | 0.94 | 1.00 | 0.95 | 0.91 | 1.31 |
| Research & Development to Revenue | 6.31 | 6.83 | 6.73 | 0.29 | 0.41 |
| SG&A to Revenue | 1.34 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.72 | 1.06 | 0.00 | 0.06 | 0.08 |
| Income Quality | 0.89 | 0.86 | 1.27 | 3.22 | -0.09 |
Currency in USD

